Resverlogix Corp. has announced key scientific data was presented in an oral presentation highlighting the novel features of RVX-208 at the American Heart Association Scientific Meeting. The presentation titled “Compound RVX-208 Modulates HDL-C Levels and Function in Non-human Primates and in Early Human Trials” was presented by Dr. Jacques Genest.
Navigation
Daily News
- Cardiac Catheterizations: Too Many Performed?
- Salmonella Risk Prompts Wider Food Recall
- Diamyd Medical: Diamyd US Phase III Study Well Under Way
- WHO Releases New Malaria Guidelines For Treatment And Procurement Of Medicines
- ONC Publishes EHR Certification Rule
Translator
 |  |  |  |  |  |  |  |  |  |
 |  |  |  |  |  |  |  |  |  |
 |  |  |  |  |  |  |  | ||
| By N2H | |||||||||